Deucravacitinib is an allosteric inhibitor that binds to the pseudokinase JH2 (regulatory) domain of Tyk2; this unique mechanism determines greater selectivity and a reduced risk of adverse events. In September 2022, deucravacitinib became the first Tyk2 inhibitor approved for the treatment of moderate-to-severe psoriasis.

2024年3月11日 · The TYK2 inhibitor deucravacitinib is now approved for the treatment of psoriasis on the basis of positive phase III trials, whereas preliminary evidence of the efficacy of deucravacitinib in...

Tyrosine kinase 2 (Tyk2) is associated with receptor subunits of immune-related cytokines, such as type I interferon, interleukin (IL)-6, IL-10, IL-12, and IL-23. Clinical studies on the therapeutic effects and the underlying mechanisms of Tyk2 inhibitors in autoimmune or chronic inflammatory diseases are currently ongoing.

About ESK-001 . ESK-001 is an investigational next-generation tyrosine kinase 2 (TYK2) inhibitor that is designed to correct immune dysregulation across a spectrum of diseases driven by proinflammatory mediators, including IL-23, IL-17, and type 1 interferon (IFN). 1,2. ESK-001's selective targeting is designed to deliver maximal inhibition while minimizing off-target binding …

2023年8月14日 · Deucravacitinib, a first-in-class allosteric TYK2 inhibitor, represents a remarkable advancement in the field. Rather than competing at kinase domain catalytic sites as classical JAK1-3 inhibitors, deucravacitinib targets the regulatory pseudokinase domain of TYK2.

2025年3月9日 · A once-daily TYK2 inhibitor was safe and “highly effective” in adults with moderate to severe plaque psoriasis, according to a presenter. Image: Adobe Stock.

2024年2月6日 · Provided herein are novel TYK2 inhibitors, pharmaceutical compositions, use of such compounds in treating autoimmune and inflammatory diseases, and processes for preparing such compounds.

2022年10月11日 · TYK2 inhibitors work by blocking the TYK2 protein and the cellular signals that run through it. Those signals can in turn activate other immune proteins and are associated with inflammation.

2024年11月1日 · Tyk2 inhibitors offer a potentially exciting new treatment option across a wide range of autoimmune diseases. We discuss Tyk2 inhibition, the current evidence for its usage to date, ongoing trials and what the future might hold.

Myrobalan’s brain-penetrant allosteric TYK2 inhibitor demonstrates robust suppression of inflammatory cascades with minimal off-target effects. Preliminary data reveal superior potency and exceptional blood-brain barrier penetration, while maintaining high selectivity against other Janus kinases (JAKs).